Cyclo Therapeutics Reports Positive Data From Phase 1 Study On Trappsol Cyclo For NPC Treatment

Cyclo Therapeutics Inc. (CYTH) announced new positive safety and efficacy data from ongoing phase 1 open-label extension study of trappsol cyclo for the treatment of niemann-pick disease type C1 or NPC. NPC is a rare, progressive and fatal genetic disorder characterized by abnormal accumulation of cholesterol in cells.

The data provide additional support for the capacity of Trappsol Cyclo to stabilize disease progression with home-based intravenous infusions in Niemann-Pick Disease Type C1, the company said in a statement.

Trappsol Cyclo is currently being evaluated in the pivotal Phase 3 study, TransportNPC, for the treatment of NPC1. Cyclo Therapeutics received Orphan Drug Designation for Trappsol Cyclo to treat NPC1 in both the US and EU and Fast Track and Rare Pediatric Disease Designations in the US.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Omnichannel retailer Macy's, Inc. announced Monday plans to hire colleagues for more than 41,000 full- and part-time seasonal positions for the upcoming holiday season. The colleagues will be positioned at its Macy's, Bloomingdale's and Bluemercury stores, supply chain locations and call centers. Seffner, Florida -based Canyon Furniture Co. is recalling ladders sold with bunk bed and hutch sets citing entrapment and strangulation risks, the U.S. Consumer Product Safety Commission said. The about 2,100 units of Canyon Lake and Cottage Colors Bunk Bed and Hutch Sets were sold exclusively at Rooms To Go. Lyft announced the expansion to its partnership with Indeed in Jobs Access program. The ride-hailing company will be providing transportation access for Indeed's Ready to Work program. Indeed's Ready to Work program is a series of free virtual and in-person events for job seekers in several cities across the U.S. from September 15 to October 8, 2022.
Follow RTT